Related Experiment Video
Updated: Aug 15, 2026

Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection
Published on: March 14, 2019
[Treatment of adynamic bone disease with the complete replacement from calcium carbonate to sevelamer hydrochloride]
Toru Hyodo1, Haruki Wakai, Toru Takemura
1Dialysis center, Yokohama Dai-ichi Hospital.
Insights
Sevelamer hydrochloride effectively treats adynamic bone disease in hemodialysis patients, improving bone turnover. However, careful monitoring is needed to prevent osteitis fibrosa development.
Area of Science:
- Nephrology
- Bone Metabolism
- Pharmacology
Context:
- Adynamic bone disease (ABD) is a common complication in maintenance hemodialysis (HD) patients.
- Traditional treatments for ABD have limitations.
- The study investigates a novel therapeutic approach for ABD in HD patients.
Purpose:
- To evaluate the therapeutic efficacy of sevelamer hydrochloride (SH) in inducing hypocalcemic stimulation for treating adynamic bone disease (ABD).
- To assess the changes in bone turnover markers in HD patients undergoing SH treatment.
- To identify potential adverse effects associated with SH administration for ABD.
Summary:
- Twenty-eight maintenance hemodialysis patients with ABD were treated with sevelamer hydrochloride (SH).
- Patients initially received calcium carbonate (CC) and SH, transitioning to SH monotherapy.
- Bone turnover was assessed using intact-osteocalcin (iOC) levels at baseline, 6, and 12 months.
- At 12 months, 32.1% of patients achieved normal bone turnover (NTB), while 3.6% developed osteitis fibrosa.
Impact:
- Sevelamer hydrochloride shows promise as an effective treatment for adynamic bone disease in hemodialysis patients.
- The study highlights the potential for SH to improve bone metabolism and normalize bone turnover.
- Caution is advised regarding the risk of developing osteitis fibrosa, necessitating careful patient monitoring.
Abstract:
The aim of this study was to examine the therapeutic effect of hypocalcemic stimulation caused by sevelamer hydrochloride (SH) administration on adynamic bone disease (ABD). The subjects were 28 maintenance hemodialysis (HD) patients who had remained in ABD state in spite of no administration of vitamin D(3) since HD induction (15 males and 13 females;12 diabetic patients and 16 non-diabetic patients). The mean age was 61.8+/-9.5 years and the mean HD duration was 5.5+/-3.9 years. The calcium concentration in the dialysate was 3.0 mEq/L. We made the final daily dose of SH after two months the same as the first daily dose of calcium carbonate (CC) in the following manner. At first we administered only CC at breakfast and lunch and SH at supper. And for the next two weeks we administered CC at breakfast and SH at lunch and supper. And for the final two weeks we administered only SH. After that we increased the dose of SH as much as possible. We evaluated the therapeutic effect of the above treatment on ABD using intact-osteocalcin (iOC) [Teijin. Tokyo] as a marker before and 6, 12 months after the beginning of the replacement. If iOC Ievel of 30 to 70 ng/mL showed normal tumover bone (NTB), 5 cases (17.9%) changed into NTB in 6 months. 9 cases (32.1%) changed into NTB in 12 months and one case (3.6%) changed into ostitis fibrosa in 12 months. It is thought that SH is effective for the treatment of ABD but we have to be careful for ostitis fibrosa.
Related Concept Videos
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Bone Remodeling
Skeleton and Calcium Homeostasis
What is the Skeletal System?
Bone Remodeling and Repair
Osteoclasts in Bone Remodeling
